Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles (2011 - 2016)
Arrowhead Pharmaceuticals (ARWR) posted Amortizatization of Intangibles of $30556.0 for Q3 2016, up 39.61% on a QoQ basis from $21886.0 in Q2 2016, and down 81.53% year-over-year from $165410.0 in Q4 2015.
Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles (2011 - 2016) Analysis & Trends
Arrowhead Pharmaceuticals' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $30556.0 for Q3 2016.
- Quarterly Amortizatization of Intangibles fell 81.53% year-over-year to $30556.0 in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $231902.0 (down 79.12% YoY) and the FY2016 annual result came in at $231902.0, down 79.12% from the prior year.
- Amortizatization of Intangibles was $30556.0 for Q3 2016 at Arrowhead Pharmaceuticals, up from $21886.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $377596.0 in Q3 2014 and bottomed at -$26918.0 in Q2 2012.
- A 5-year average of $119490.8 and a median of $46065.0 in 2013 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2013 — Amortizatization of Intangibles surged 4872.55% — and 2016, when it slumped 92.09%.
- Arrowhead Pharmaceuticals' Amortizatization of Intangibles stood at $572.0 in 2012, then jumped by 4872.55% to $28443.0 in 2013, then surged by 1122.46% to $347703.0 in 2014, then plunged by 68.82% to $108403.0 in 2015, then slumped by 71.81% to $30556.0 in 2016.
- Business Quant data shows ARWR's Amortizatization of Intangibles at $30556.0 in Q3 2016, $21886.0 in Q2 2016, and $71057.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.26 Bn | 10.47 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 30,556.00 |
| Sep 30, 2016 | 30,556.00 |
| Jun 30, 2016 | 21,886.00 |
| Jun 30, 2016 | 21,886.00 |
| Mar 31, 2016 | 71,057.00 |
| Mar 31, 2016 | 71,057.00 |
| Dec 31, 2015 | 108,403.00 |
| Dec 31, 2015 | 108,403.00 |
| Sep 30, 2015 | 165,410.00 |
| Sep 30, 2015 | 165,410.00 |
| Jun 30, 2015 | 276,750.00 |
| Jun 30, 2015 | 276,750.00 |
| Mar 31, 2015 | 320,661.00 |
| Mar 31, 2015 | 320,661.00 |
| Dec 31, 2014 | 347,703.00 |
| Dec 31, 2014 | 347,703.00 |
| Sep 30, 2014 | 377,596.00 |
| Sep 30, 2014 | 377,596.00 |
| Jun 30, 2014 | 146,978.00 |
| Jun 30, 2014 | 146,978.00 |